- Evolution of anti-CD20 monoclonal antibody therapeutics in oncologyEzogelin Oflazoglu
Merck Bioventures, Discovery Biologics, Merck and Co, Inc, Rahway, NJ, USA
MAbs 2:14-9. 2010....
- Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicitySvetlana O Doronina
Seattle Genetics, Inc, 21823 30th Drive SE, Bothell, Washington 98021, USA
Bioconjug Chem 17:114-24. 2006..Thus, alterations of the linker have pronounced impacts on toxicity and lead to new ADCs with greatly improved therapeutic indices...